COMMUNIQUÉS West-GlobeNewswire

New MotherToBaby Study Targets Pregnancy Data Gap for Newer Eczema Treatment
13/08/2026
The FDA has determined that human pregnancy data for Ebglyss® remain insufficient. By enrolling U.S. and Canadian participants, this study will help generate the evidence needed to inform future treatment decisions. San [...]
Arisan Therapeutics Selected for NIAID Contract Award to Develop a Therapeutic Small Molecule Viral Entry Inhibitor as a Medical Countermeasure for Filovirus Infection
13/08/2026
Contract Valued at Up to $24 million Supports IND-Enabling Studies for Arisan’s Lead Candidate with Demonstrated Activity Against Multiple Ebolaviruses CARLSBAD, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Arisan [...]
Early-Bird Deadline Approaches for 2nd Annual Guardian Initiative Charity Golf Tournament as Veterans Seek Sponsors to Play
13/08/2026
Players have until August 28 to take advantage of early-bird pricing for the September 28 charity tournament at Maderas Golf Club, while local veterans are seeking sponsors for the opportunity to participate. San Diego [...]
Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026
13/08/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first six months of 2026 in the morning on Thursday, 20 August 2026. Later on the same day, the company will host a presentation for investors [...]
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
13/08/2026
SYMON-II pivotal clinical study completes targeted enrollment of 750 patients Company advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain risk [...]
Zelluna ASA: Invitation to Second Quarter 2026 Results Webcast Presentation
13/08/2026
Oslo, Norway, 13 August 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation [...]
ApolloMD Names Brianna Watson 2026 Emergency Medicine Scholarship Winner
13/08/2026
Howard University medical student receives $5,000 award for essay on technology, environmental health and emergency medicine ATLANTA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ApolloMD has named Brianna Watson, a fourth-year [...]
Vireo Growth Inc. Announces Share Buyback Program
13/08/2026
MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), a leading vertically integrated cannabis company and agricultural markets platform, today announced [...]
Montauk Brewing Company Announces New Collaboration with Morning Brew Inc.
13/08/2026
The Morning Brew, a Blonde Ale featuring Roasted Coffee Beans, is on tap now MONTAUK, N.Y., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Montauk Brewing Company , the coastal lifestyle brand by Tilray Brands, Inc. (NASDAQ: TLRY [...]
Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2026 Guidance
13/08/2026
Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period Second Quarter Net income was $40.3 million compared to $27.0 million for the prior year period Adjusted EBITDA for Q2 2026 was $95. [...]
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
13/08/2026
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Photys Therapeutics and Polymed Biopharmaceuticals Announce the Initiation of a Phase I Clinical Trial of PHT-776/HPB-143, an Oral IRAK4 PROTAC Degrader
13/08/2026
WALTHAM, Mass. and HANGZHOU, China, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Photys Therapeutics, Inc. (“Photys”), a proximity-based therapeutics company, and Polymed Biopharmaceuticals, Inc. (“Polymed”), a global biotech [...]
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid ® Second [...]
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab single-dose prefilled autoinjector pen compared [...]
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
13/08/2026
Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data from the MICVO [...]
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
13/08/2026
10 ALLY Robotic Cataract Laser Systems ® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser Installed Base [...]
6 Stress Points That Break Retail Customer Service During Peak Season
13/08/2026
The Retail and Ecommerce Peak Resilience Index from Transcom, with a free eight-question stress test, is now available and classifies operations as fragile, reactive, elastic, or adaptive. Six volatility stress points [...]
American Shared Hospital Services Reports Second Quarter and First Half 2026 Financial Results
13/08/2026
Second Quarter Revenue Increased 19% to $8.4 Million Driven by Strong Growth from Direct Patient Services Operating Cash Flow Reached $4.4 Million in First Half of 2026 Conference Call Scheduled for Today at 1:00 PM ET [...]
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for [...]

Pages